DHFR Inhibitors Display a Pleiotropic Anti-viral Activity Against SARS-CoV-2: Insights Into the Mechanisms of Action
Authors:
- Daniela IaconisDIDaniela Iaconis
- Francesca CaccuriFCFrancesca Caccuri
- Candida ManelfiCMCandida Manelfi
- Carmine TalaricoCTCarmine Talarico
- Antonella BugattiABAntonella Bugatti
- Federica FilippiniFFFederica Filippini
- Alberto ZaniAZAlberto Zani
- Rubina NovelliRNRubina Novelli
- Maria KuzikovMKMaria Kuzikov
- Bernhard EllingerBEBernhard Ellinger
- Philip GribbonPGPhilip Gribbon
- Kristoffer RieckenKRKristoffer Riecken
Preprint
- 6 April 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
During COVID-19 pandemic, drug repurposing represented an effective strategy to obtain quick answers to medical emergencies. Basing on previous data on Methotrexate (MTX), we evaluated the anti-viral activity of several DHFR inhibitors in two cell lines. We observed that this class of compounds showed a significant influence on the virus-induced cytopathic effect (CPE) partly associated to the intrinsic antimetabolic activity of these drugs, but also to a specific antiviral function. To elucidate the molecular mechanisms, we took advantage of our EXSCALATE platform for in-silico molecular modelling and further validated the influence of these inhibitors on nsp13 and viral entry. Interestingly, Pralatrexate and Trimetrexate showed superior effects in counteracting the viral infection compared to other DHFR inhibitors. Our results indicate that their higher activity is due to their polypharmacological and pleiotropic profile. These compounds can thus potentially give a clinical advantage in the management of SARS-CoV-2 infection in patients already treated with this class of drugs.Keywords
All Related Versions
- Version 1, 2023-04-06, Preprints
- Published version: Viruses, 15 (5), 1128.
This publication has 64 references indexed in Scilit:
- Identification of Risk Factors for COVID‐19 Hospitalization in Patients With Anti‐Rheumatic Drugs: Results From a Multicenter Nested Case Control StudyClinical Pharmacology & Therapeutics, 2022
- COVID-19 and Disease-Modifying Anti-rheumatic DrugsCurrent Rheumatology Reports, 2021
- Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”Journal of Medical Virology, 2020
- A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)Naunyn-Schmiedeberg's Archives of Pharmacology, 2020
- A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritisCancer Chemotherapy and Pharmacology, 2013
- Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancersCancer Chemotherapy and Pharmacology, 2009
- Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic linesInflammation Research, 2005
- Novel antifolate drugsCurrent Oncology Reports, 2003
- Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX‐68Arthritis & Rheumatism, 2003
- A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in miceCancer Chemotherapy and Pharmacology, 1998